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Abstract 
The fate and activity of drugs are frequently dictated not only by the host per se but also by 
the microorganisms present in the gastrointestinal tract. The gut microbiome is known to, 
both directly and indirectly, affect drug metabolism. More evidence now hints at the impact 
that drugs can have on the function and composition of the gut microbiome. Both microbiota-
mediated alterations in drug metabolism and drug-mediated alterations in the gut microbiome 
can have beneficial or detrimental effects on the host. Greater insights into the mechanisms 
driving these reciprocal drug-gut microbiota interactions are needed, to guide the 
development of microbiome-targeted dietary or pharmacological interventions, with the 
potential to enhance drug efficacy or reduce drug side-effects. In this review, we explore the 
relationship between drugs and the gut microbiome, with a specific focus on potential 
mechanisms underpinning the drug-mediated alterations on the gut microbiome and the 
potential implications for psychoactive drugs. 
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Introduction  
Although not prominently featured in the classical teaching of pharmacokinetics and 
pharmacodynamics (PKPD), the fate and activity of drugs are frequently decided not only by 
the host per se but also by the collection of microorganisms present in the gastrointestinal 
(GI) tract. These microorganisms represent the gut microbiota; the trillions of microbes with 
more than 700-1000 different bacterial species which reside in the gut (Qin et al. 2010). The 
terms microbiota and microbiome are often used interchangeably in the literature but can be 
differentiated based on their more recent definitions. The term “microbiota” refers to the 
collection of microorganisms whereas the term “microbiome” refers to the collective 
genomes of these microorganisms (Jandhyala et al. 2015; Marchesi et al. 2015). It’s 
estimated that ten different phyla are thought to contribute to the functional role of the gut 
microbiome; Firmicutes and Bacteroidetes are the most dominant phyla. Indeed, the ratio of 
Firmicutes to Bacteroidetes (F/B ratio) is often used as a surrogate indicator of bacterial shifts 
although it may be an overly simplistic descriptor of variations in human gut microbiota 
composition (Mariat et al. 2009).  Many factors have been identified that influence the 
biogeography and composition (both abundance and diversity) of bacteria along the GI tract 
including pH variation, diet, mucus, host immunity and environmental factors (Thursby and 
Juge 2017). For example, the acidic environment of the stomach has a sparse microbiota (10
1
 
bacteria/g) compared to the estimated 10
3 
bacteria/g found in the less acidic small intestine, 
which is the main site of drug absorption. The neutral pH or weakly basic environment found 
in the large intestine is the most densely colonised area of the GI tract, with an estimated 10
12 
bacteria/g (O'Hara and Shanahan 2006).  
The gut microbiome is predominantly implicated in the maturation of the immune system, 
nutrient absorption, energy homeostasis and protection against pathogens (Antunes et al. 
2011; Jandhyala et al. 2015). It also plays a significant role in health, both in homeostasis 
and, likely, in the pathogenesis and treatment of disease. The initial composition and 
assembly of the gut microbiome are considered unique amongst individuals and research has 
identified many factors which impact its’ composition including age, ethnicity, gender, 
environmental factors, diet, and lifestyle (Quigley 2017). For example, the composition of the 
gut microbiota in the newborn is dictated by the method of delivery, gestational age, infant 
antibiotic exposure, and method of feeding (formula versus breastfeeding) (Penders et al. 
2006; Salazar et al. 2014). Though considered highly stable and resilient to change during 
adulthood, instability and variability in the gut microbiome become more prevalent during 
disease and at the extremes of life (e.g. early infancy and senescence)  (Salazar et al. 2014). 
The young and the old are also considered to be the most vulnerable patient groups regarding 
the occurrence of adverse drug reactions and display the most variation in drug 
pharmacokinetic responses (Turnheim 2003). 
The implication of the gut microbiome in drug metabolism is gaining more traction and has 
led to the emergence of a new term, Pharmacomicrobiomics (Rizkallah et al. 2010). 
Pharmacomicrobiomics investigates the effect of variations of the gut microbiome on drugs, 
through the lens of PKPD. In this review, we explore the relationship between drugs and the 
gut microbiota, with a specific focus on the potential mechanisms underpinning the drug-
mediated alterations on the gut microbiota and the potential implications for the 
pharmacokinetic and pharmacodynamic profile of drugs. With the increasing development of 
extended-release drug formulations, especially in the field of neuropharmacology, which may 
increase the proportions of the drug reaching the bacterially-dense large intestine, a higher 
number of psychoactive drugs, which are subject to microbiota-mediated degradation, may be 
identified. While the gut microbiome may affect all classes of drugs, the purpose of this 
review is to focus specifically on psychoactive drugs given that most of these drugs display 
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high lipophilicity to ensure central nervous system (CNS) penetration (Alavijeh et al. 2005). 
In general, highly lipophilic drugs are at greater risk of poor drug absorption from the 
intestine hence any microbial-mediated changes in intestinal absorption or metabolism merit 
further consideration.  Developing a greater understanding of these important, but 
underappreciated, drug-microbiota dynamics could help to identify drug-drug interactions 
and perhaps explain inter-individual variation in drug efficacy and adverse effects. 
 
1 The Effects of Drug Therapy on the Gut Microbiome 
1.1 Drug effects on the gut microbiome: 
Recently, two large-scale human observational studies highlighted correlations between the 
gut microbiota and the intake of different classes of medication. Falony et al. compared the 
composition of the gut microbiota against the use of β-lactam antibiotics, nitrofuran 
antibiotics (nitrofurantoin), an osmotic laxative, biologics (TNF-α inhibitor), disease 
modifying anti-rheumatic drugs (DMARDS; mesalazine and azathioprine), estrogen and 
progesterone hormones, benzodiazepines (clonazepam), anti-depressants (venlafaxine), and 
anti-histamines (Falony et al. 2016). While 95% of samples had a similar core microbiome, 
medication exposure was identified as the factor causing greatest variability in the study 
cohort, with 63% of the detected covariate interactions driven by medication. A positive 
correlation, for example, was identified between the abundance of a species from the 
Eggerthella and Coprabacillus genera and medication use. In another metagenomic-based 
study, Zhernakova et al. identified extrinsic and intrinsic factors correlating with microbial 
shifts in a Dutch-population study. Forty-four categories of drugs were tested in the analysis 
and antibiotics, gastric-acid suppressants (proton pump inhibitors, PPIs), lipid-lowering 
medication (3-hydroxy-3-methylglutaryl coenzyme reductase inhibitors or “statins”), anti-
hyperglycaemic (metformin), and laxatives were found to have a distinct impact on the gut 
microbiome. PPIs were, for example, associated with profound changes in 33 bacterial 
pathways and metformin-use positively correlated with Escherichia coli abundance 
(Zhernakova et al., 2016). While a wide range of medication has been identified to interact 
with the gut microbiota, certain drug classes including antibiotics, anti-inflammatories, acid-
suppressants, anti-hyperglycaemics and psychotropics, have repeatedly been shown to have 
distinct gut microbiota signatures and will be discussed further in the review (Section 3.2 and 
4.5).  
1.2 Combination of drugs and polypharmacy: 
The composition of the microbiota can vary depending on both the number and combination 
of medication ingested. A significant difference in microbiota composition was observed in 
patients taking a single drug on a long-term basis in comparison to non-drug taking patients 
(Rogers and Aronoff 2016). Moreover, the combined use of non-steroidal anti-inflammatory 
drugs (NSAIDs) and PPIs differentially influenced the relative abundance of Bacteroides spp. 
and Erysipelotrichaceae spp. compared to NSAIDs alone. Similarly, Bacteroides spp. and a 
species belonging to the Ruminococcaceae family differentiated individuals who were 
concomitantly taking NSAIDs, antidepressants, and laxatives from NSAID-only users. 
Therefore, the composition of the gut microbiota may depend on an individual’s drug use.  In 
this study, the diversity of the gut microbiota was not significantly influenced by the number 
of medications taken, even though it was significantly influenced by the specific type of 
medication ingested by study participants. Of note, the median number of medications taken 
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by the community-dwelling subjects was four, which falls below the threshold for 
polypharmacy. Once this threshold is reached (i.e. ≥five concomitant taken medication), an 
impact is frequently observed. A significant decrease in species richness, a measurement of 
the number of species present in an area, and significant alterations in the relative abundance 
of 15 bacterial taxa have been reported in patients taking more than five concomitant 
medications (Ticinesi et al. 2017). Specifically, the relative abundance of the Helicobacter 
genus was significantly associated with polypharmacy and, an inverse relationship between 
polypharmacy and the abundance of the Lachnospiraceae and Succinivibrionaceae families 
was also found. The co-administration of drugs may precipitate shifts in the composition of 
the microbiota to favour the abundance of microbial taxa that have metabolising capacity for 
those drugs (Ticinesi et al. 2017). Not only is it important, therefore, to evaluate specific 
microbiota alterations induced by a single drug but it’s also imperative to account for 
differences when multiple drugs are co-administered. Further study of the impact of multiple 
co-administered drugs on the gut microbiota is very relevant due to the increasing prevalence 
of polypharmacy in the ageing population (Dagli and Sharma 2014). In a European study 
across eight countries, the prevalence of polypharmacy in 4023 nursing home residents, the 
mean age of whom was 83.5 (SD 9.3) years, was found to be 49.7% whilst excessive 
polypharmacy (defined as ≥10 medication) was evident in an additional 24.3% of residents, 
which serves to highlight the potential for drug-associated effects on the microbiota in a 
vulnerable population in which the gut microbiome is already compromised (Claesson et al. 
2012; Onder et al. 2012).  
 
1.3 Duration of drug treatment and recovery: 
There is some in vitro evidence to suggest that even single antibiotic dose or short-term 
antibiotic courses, albeit at high doses, can significantly impact the microbiome (Maurice et 
al. 2013). Specifically, eight different antibiotics altered the faecal microbiota after a four-
hour incubation, and a significantly increased proportion of cells associated with loss of 
membrane integrity and altered polarity was observed. Most antibiotic-induced alterations to 
the microbiome are reversed upon cessation of treatment. Some modifications can, however, 
persist after treatment (Jakobsson et al. 2010). For example, the combined treatment of the 
antibiotics clarithromycin and metronidazole with a proton pump inhibitor, omeprazole, 
induced alterations to macrolide resistance gene, ermB, which persisted in patients for up to 
four years after treatment.  
Additionally, the antipsychotic, risperidone is associated with a reduction in the F/B ratio 
which was evident at the 2-3 month study follow-up of treatment but a further reduction in 
Bacteroidetes, and increased weight gain, was observed after prolonged use (Bahr et al. 
2015a). The continued use of drugs may, therefore, strengthen microbiota alterations, which 
may be evident from initiation of treatment but further comparisons between short-term and 
long-term users of medication are required.  
 
1.4 Excipient effects: 
An excipient is a pharmacologically inert substance or non-active ingredient that is added to a 
formulation to stabilise the active substance or enhance the function of the dosage form 
(Debotton and Dahan 2017). Most excipients are not absorbed from the gut lumen. Moreover, 
 
This article is protected by copyright. All rights reserved. 
polysaccharide-based formulations are often utilised in the delivery of probiotics and colonic-
targeted drug dosage forms, for example, targeted local delivery of the anti-inflammatory 
sulfasalazine (Kosaraju 2005; Prudhviraj et al. 2015). Recent research hints at the possibility 
that the excipients themselves in the drug formulation might mediate microbiota changes, 
independent of changes induced by the drug. Recently, it was hypothesised that the presence 
of fermentable polysaccharides as drug formulation excipients may act as metabolic 
substrates for the gut microbiota thereby promoting their growth (Ticinesi et al. 2017). 
Additionally, polyethylene glycol (PEG), a polymer used in drug delivery, is linked to 
changes in GI transit time and changes in the gut microbiota (Kashyap et al. 2013). 
Humanised mice (ex-germ-free mice colonised with human faecal microbiota), fed a standard 
diet supplemented with 15% PEG 3350 for 10 days, had significantly reduced abundance of 
the Peptococcaceae, Eubacteriaceae bacterial families and the Anaeroplasmataceae order. As 
the dosage used in this animal study is detailed as %w/w of the animal chow, it is, however, 
difficult to extrapolate this dose to that used in pharmaceutical formulations. PEGs are 
commonly included in dosage forms, with diverse excipient functions including as 
solubilising agents, tablet binders, plasticisers in film coating, tablet lubricants and vehicles 
(D’souza and Shegokar 2016). Additional studies are warranted to elucidate the potential 
effect of the different categories of PEG polymers used in drug formulations at 
pharmaceutically-relevant concentrations. Excipient-induced changes in the composition or 
functionality of the microbiome could potentially complicate the interpretation of drug-
microbiota based observational studies as it may be challenging to differentiate drug-induced 
changes from excipient-induced changes in the gut microbiome. Greater research is needed to 
evaluate the independent effects of different formulation excipients, and the possible 
unintended consequences their inclusion in drug formulations could have on the gut 
microbiome.  
 
1.5 Gut microbiome drug-drug interactions: 
Drug-induced changes in the gut microbiome may alter the pharmacokinetics of concomitant 
taken medication. An increased plasma level of the antiplatelet drug, aspirin, was observed in 
rats who were treated with a β-lactam antibiotic, ampicillin, three days previous (Kim et al. 
2016). This enhanced bioavailability was attributed to the antibiotic-induced suppression of 
the metabolic activity of the gut microbiome. Moreover, ampicillin treatment significantly 
prolonged bleeding time in aspirin-treated rats, suggesting antibiotic treatment may potentiate 
its anti-thrombotic effect. Similar microbiome-mediated drug interactions have been 
demonstrated for both the lipid-lowering drug, lovastatin and the antihypertensive, 
amlodipine (Yoo et al. 2014; Yoo et al. 2016). 
 
2 Gut Microbiota-Drug Interactions 
 
The gut microbiome can both directly metabolise drugs and indirectly influence host 
metabolising capacity of drugs (Haiser and Turnbaugh 2013; Wilson and Nicholson 2017). 
While many drugs undergo microbial biotransformation, the specific microorganisms 
involved are often unknown. In this review, we will mainly refer to bacterial drug-
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metabolising enzymes and the impact of the gut microbiome on the metabolism of drugs by 
the liver, as the primary focus of the review is the reciprocal impact drugs can have on the gut 
microbiome, a relatively unexplored and unappreciated area in the literature. Microbial drug 
metabolism has been extensively reviewed recently (Koppel et al. 2017; Wilson and 
Nicholson 2017).  
2.1 Drug metabolism by microbial enzymes: 
Microbial-derived drug metabolising enzymes have been implicated both in the activation 
and inactivation of drugs. For example, the activation of the prodrug sulfasalazine into its 
anti-inflammatory active moiety mesalazine (5aminosalicyclic acid or 5-ASA) is mediated by 
bacterial azoreductase (Peppercorn and Goldman 1972). The direct metabolism of drugs by 
microbial-derived enzymes has been shown for a variety of different drugs, examples of 
which are detailed in Table 1. In contrast to the oxidation and conjugation reactions 
characteristic of hepatic metabolism, reduction and hydrolysis reactions dominate gut 
microbiota-mediated metabolic reactions (Haiser and Turnbaugh 2013). β-glucuronidase is 
amongst the most studied bacterial drug-metabolising enzymes due to its role in the 
deconjugation of hepatically-glucuronidated metabolites and the resultant enterohepatic 
recycling of drugs (Takasuna et al. 1998; Klaassen and Cui 2015). Multiple different 
bacterial genera, including Clostridium, Streptococcus, Lactobacillus, Ruminococcus and 
Bifidobacterium, express β-glucuronidase (Gloux et al. 2011).  
The development of a chemically-guided functional strategy to identify, quantify and assign 
functionality of enzymes associated with the gut microbiome is amongst the recent advances 
in this area. This strategy unravelled the discovery of trans-4-hydroxy-L-proline dehydratase 
microbial enzyme implicated in the metabolism of a non-proteinogenic amino acid, trans-4-
hydroxy-L-proline (Levin et al. 2017). Application of this strategy for the identification and 
characterisation of microbial drug-metabolising enzymes holds much potential and could 
uncover previously unknown metabolic activity of the gut microbiome.  
2.2 Indirect effects of the gut microbiome on host drug metabolism: 
It was traditionally assumed that only drugs reaching the colon are subject to microbiota-
associated alterations with relevance to drug PKPD. The concerted role of the gut bacteria 
and the liver in the enterohepatic recirculation of drugs is not a new concept (Takasuna et al. 
1998). However, more recently it was highlighted that the gut microbiome could also 
influence hepatic function which may, in turn, precipitate changes in patient response to 
drugs. 
Microbial-derived metabolites can mimic and compete with drug intermediates of hepatic 
metabolic reactions and thereby interfere with host detoxification pathways. For example, P-
cresol is a microbial metabolite of tyrosine or phenylalanine which competes with 
paracetamol for the hepatic enzyme, sulfotransferase family 1A member 1 (SULT1A1) 
(Clayton et al. 2009). This competition for SULT1A1 induces a shift in the metabolism of 
paracetamol towards alternative host metabolic reactions leading to increased production of 
the paracetamol metabolite, N-acetyl-4-benzoquinoneimine (NAPQI); the accumulation of 
which has been associated with hepatotoxicity (Mitchell et al. 1973). 
Moreover, the gut microbiome can alter the expression of hepatic enzymes or genes 
responsible for host metabolism. Claus et al. detected significantly reduced expression of 
hepatic cytochrome P450 (CYP) 2c29, CYP3a11 and CYP8b1 in germ-free (GF) mice in 
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comparison to conventionally-raised control mice (Claus et al. 2011). Increased expression of 
hepatic drug-sensing transcription factors has also been observed in GF mice including, for 
example, the aryl hydrocarbon receptor, a regulator of downstream CYP enzyme expression 
(Selwyn et al. 2015). However, the mechanisms responsible for the microbiome-induced 
changes in the expression of hepatic enzymes requires further exploration. The accumulation 
of bilirubin, bile acids and steroid hormones in GF mice has been suggested as a potential 
mechanism mediating the altered activation of the constitutive androstane receptor, a 
“xenosensor” nuclear receptor, and further implicates an indirect role for the microbiome in 
drug metabolism (Björkholm et al. 2009).  
2.3 Effect of diet-induced changes on the gut microbiome and drug 
pharmacokinetics:  
Diet is a factor that can shape the composition and function of the gut microbiome (Sandhu et 
al. 2016; Shanahan et al. 2017). It is plausible that in the future dietary interventions may be 
utilised to augment drug efficacy or decrease toxicity. The amino acid arginine has been 
shown to inhibit the Eggerthella lenta-encoding cgr operon, previously identified as essential 
for the microbiota-mediated reduction of the cardiac glycoside, digoxin (Haiser et al. 2013). 
Following confirmation of high levels of cgr operon expression, E. lenta colonised GF mice 
were fed a high-protein diet and significantly increased serum and urine levels of digoxin 
(following a single 0.2 mg/ml intra-gastric digoxin dose) were identified. Interestingly, high 
protein diet conferred no effect on digoxin pharmacokinetics in GF mice colonised with a 
non-digoxin reducing strain, FAA1-3-56, ruling out any indirect effect of host diet. Increased 
dietary protein, leading to increased arginine, could thus constitute a potential dietary 
intervention to improve digoxin efficacy. Recent data has also elucidated the role of diet-
induced changes in the gut microbiota on the oral bioavailability of the herbal supplement, 
berberine (BBR), used for the treatment of hyperlipidaemia and type 2 diabetes (Wang et al. 
2017). BBR bioavailability was significantly increased in high-fat diet (HFD) fed hamsters in 
comparison to hamsters fed a normal diet. The HFD significantly induced bacterial nitro-
reductase activity in hamster faeces. The authors also observed higher blood BBR 
concentrations in individuals with a higher faecal nitro-reductase activity which further 
corroborated the findings in their animal model. 
2.4 Effect of probiotics on drug pharmacokinetics:  
Microbiota-targeted interventions, including probiotics, prebiotics, and antibiotics, may alter 
drug pharmacokinetics. There are no studies thus far, to our knowledge, exploring the impact 
of probiotics on psychoactive drug absorption and metabolism. The pharmacokinetics of an 
oral hypoglycaemic agent, gliclazide (administered as a single dose at 20 mg/kg) was 
significantly altered in diabetic rats pre-treated with a cocktail of three probiotics 
(Lactobacillus acidophilus, Lactobacillus rhamnosus and, Bifidobacterium lactis) for three 
days (Al-Salami et al. 2008). Similarly, probiotic treatment significantly altered the 
absorption of the anti-arrhythmic agent amiodarone (Matuskova et al. 2014). In this study, 
the probiotic E. coli strain Nissile (EcN) 1917 was administered to rats for seven days, prior 
to a single oral dose of amiodarone hydrochloride (50 mg/kg). EcN significantly increased 
amiodarone bioavailability by 43% in comparison to saline-treated control rats. No 
significant effect was observed with the treatment of a non-probiotic E. coli strain, further 
indicating the bacterial-mediated changes in drug pharmacokinetics may be strain specific. 
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Probiotics may also affect drug pharmacokinetics by modulating the composition or 
metabolic activity of the gut microbiota. Recent data showed probiotic treatment significantly 
increased the microbiota-mediated degradation of the antipyretic and analgesic, paracetamol; 
an effect suggested to be mediated by probiotic-induced modulation of gut microbial enzyme 
activity (Kim et al. 2018). In this study, the probiotic, Lactobacillus reuteri, significantly 
increased both sulfatase and arylsulfate transferase, and significantly decreased β-
glucuronidase activity during treatment, which are the bacterial enzymes implicated in 
paracetamol metabolism. Following a 24-hour washout period after pre-treatment with L. 
reuteri, a single dose of paracetamol (by IV (0.5 mg/kg) or oral gavage (10 mg/kg)) was 
administered to mice. L. reuteri significantly reduced the paracetamol plasma concentration 
to 68.4% in comparison to control mice. Similarly, administration of a probiotic cocktail 
consisting of L. acidophilus, B. lactis, and Streptococcus salivarius to rats for three days 
significantly increased azoreductase activity in ex vivo colon contents (Lee et al. 2012). The 
ex vivo incubation of sulfasalazine with colon contents significantly increased the metabolism 
of the drug. No clinical significance was observed, however, in the in vivo setting when a 
single dose of sulfasalazine (100 mg/kg) was administered to rats following pre-treatment 
with the probiotic cocktail for three days. 
 
3 Drug-Microbiome Interactions  
 
In this section, the mechanisms underpinning the drug-mediated changes to the composition 
and function of the gut microbiome will be explored. 
3.1 Antibacterial effects of drugs on the gut microbiota: 
Direct disruption of the gut microbiota, through bacteriostatic or bactericidal activity, can 
alter the metabolic capability of the microbiota and have long-term effects on host functions 
and health. Such ‘antibiotic’ induced changes have been well studied. Antibiotic therapy in 
neonates can disrupt the bacterial colonisation of the intestine and can have long-term health 
implications with links to the development of eczema, allergic rhinitis, and inflammatory 
bowel disease in later life (Rodríguez et al. 2015). Antimicrobial activity, linked to the 
depletion of “good” commensal gut microbiota, provides an impetus for the overgrowth of 
hazardous commensal bacteria (Antunes et al. 2011). For example, antibiotics can decrease 
hosts resistance against the growth of the opportunistic pathogen, Clostridium difficile 
(Theriot et al. 2016). 
Non-antibiotic drugs have also been shown to exert antimicrobial activity. In vitro studies 
have detected antimicrobial activity, against at least one bacterial strain, for a wide range of 
non-antibiotic drug classes including NSAIDs, mucolytic agents, bisphosphonates, PPIs, 
antihistamines, statins, cytostatic agents and psychotropics (Kruszewska et al. 2000; 
Kruszewska et al. 2002). Sulfasalazine and the bacterial metabolite, N-acetyl 5ASA, 
inhibited the in vitro growth of faecal anaerobic strains including C. difficile (Sandberg-
Gertzen et al. 1985; Deloménie et al. 2001). The anti-neoplastic drug, 5-fluorouracil (5-FU) 
has also shown bactericidal effects against clinical isolates of Staphylococcus aureus even at 
lower concentrations than would what be expected after i.v. administration of 5-FU (Bodet et 
al. 1985). Similarly, the antimetabolite and antifolate drug, methotrexate, displayed strong in 
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vitro antibacterial activity only against S. aureus following a surveillance study of the drug 
against a variety of microbial strains including E. coli, Pseudomonas aeruginosa and 
Candida albicans (Kruszewska et al. 2000). Non-antibiotic drugs, chiefly psychotropics, can 
also affect the gut microbiome by acting synergistically with a co-administered antibacterial 
or by modulating the activity or pathogenicity of microbes, which will be discussed later in 
the review (Section 4.5) (Martins et al. 2008).   
Recently, Maier et al. further elucidated the extensive impact of non-antibiotic drugs on the 
gut microbiota (Maier et al. 2018). The authors explored the antibacterial effects of 362 anti-
infective and 835 host-targeted drugs (all drugs screened at 20µM; a concentration deemed 
representative of the predicted concentration of the drugs reaching the bacterial-dense ileum 
and colon) in vitro against 40 bacteria found to colonise the GI tract. 24% of host-targeted 
drugs had antibacterial activity against at least one bacterial strain with 40 drugs inhibiting 
the growth of up to 10 different bacteria. Antipsychotics, chemotherapeutic agents and 
antihypertensives were amongst the host-targeted drugs exhibiting the greatest antibacterial 
activity. Certain bacteria, previously identified as being highly abundant in healthy 
individuals such as Prevotella copri and Eubacterium rectale, were found to be most 
susceptible to the host-targeted drugs. Using available data from previously published 
metagenomic based human studies, the authors validated the antibacterial effects of the drugs 
identified in their high-throughput drug screens and suggested the use of some host-targeted 
drug may increase patient susceptibility to antibiotic resistance. This study reaffirms the 
importance of accounting for drug-induced changes in the gut microbiota as a potential 
confounder in assessing compositional changes in microbiota-related studies. 
 
3.2 Secondary effects of drugs on the gut microbiome: 
Drugs can directly alter the GI tract environment (e.g. pH and transit time), mucosa integrity, 
host and bacterial metabolic activity and the production of microbial-metabolites. These 
drug-induced changes could, in turn, have secondary effects on the microbiome with the 
potential to cause drug-drug interactions. 
As the gradient of pH along the GI tract is known to influence bacterial abundance and 
diversity, drug-induced changes in gastric and intestinal pH may shape the gut microbiome 
(Walker et al. 2005; Krajmalnik-Brown et al. 2012). Imhann et al. reported changes in 20% 
of bacterial taxa and a significant decrease in alpha diversity in PPI users (211 participants) 
compared with non-users (1604 participants) (Imhann et al. 2017). Alpha diversity refers to 
the within habitat or sample diversity (a single sample value for average species diversity at 
an individual site). It usually includes species richness but also accounts for the abundance of 
the species present in the sample (Gotelli and Colwell 2001). PPI-mediated increase in the pH 
of the stomach and upper small intestine precipitated the growth of specific taxa 
(Enterococcaceae and Streptococcaceae) and increased the susceptibility of enteric mucosa 
to NSAID-induced damage (Freedberg et al. 2015). Increased abundance of gastric and faecal 
Streptococcus in PPI users has been linked to the suppression of gastric acid production and 
associated with increased risk of C. difficile infection (CDI). Moreover, PPI-use has also been 
linked to increases in expression of bacterial invasion genes, which may also mediate the 
predisposition to CDI in PPI users (Freedberg et al. 2015).  
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Additionally, GI transit time can dictate the length of exposure of the microbiota to the gut 
environment. The anti-diarrhoeal, loperamide, administered to humanised GF mice via the 
drinking water (0.1%) for 10 days, significantly increased GI transit time and altered the 
composition of the distal gut microbiota with an increased  F/B ratio and a significant 
reduction in abundance of the Lachnospiraceae family (Kashyap et al. 2013). These changes 
were reversible upon cessation of loperamide administration and normalised gut transit time.  
Drugs may also challenge both the integrity and permeability of the intestinal mucosa. The 
antihyperglycaemic drug, metformin, has been linked with mucosal modifications that 
influenced the bacterial growth of Akkermansia spp (Forslund et al. 2015). An enrichment of 
virulence factors and gas metabolism genes, mediated by the associated increase in 
Escherichia, are thought to contribute to the GI disturbances, bloating and increased 
flatulence, associated with metformin use.  
The liver is continually exposed to gut microbiota-derived metabolites, including secondary 
bile acids and short chain fatty acids (SCFAs), as it receives an estimated 70% of its blood 
supply from the intestine (Marchesi et al. 2015). Recent data proved bile acids are implicated 
in the solubilisation and absorption of lipophilic drugs (Enright et al. 2017). Drug treatment 
can, however, alter gut-microbiota production of bile salts which may subsequently impact 
the absorption and metabolism of co-administered medication. Cefoperazone, vancomycin, 
and clindamycin were identified as antibiotics associated with changes in the gut microbiota 
composition and caused decreased levels of secondary bile acids precipitating the growth and 
spore germination of C. difficile (Theriot et al. 2016). Studies have found a correlation 
between the reduced levels of SCFAs in the proximal to distal colon with the corresponding 
increase in pH from the cecum to rectum (den Besten et al. 2013). Drug-induced changes in 
the production of SCFAs could thus indirectly impact gastrointestinal pH, which as 
mentioned previously may precipitate changes in the microbiome. For example, increased 
levels of SCFAs were linked with metformin, which could instigate the microbiota 
modifications associated with this drug (Zhernakova et al. 2016).  
Secondary effects of drugs on the gut microbiome could also arise from drug-induced 
modification of genes or enzymes involved in drug metabolism or drug transport. 
Metabolomic studies have been employed to investigate the impact of antibiotics on the gut 
microbiome before and after treatment (Antunes et al. 2011). High dose treatment of mice 
with an aminoglycoside antibiotic (20 mg streptomycin via oral gavage) altered 87% of all 
detected intestinal metabolite features and affected many host metabolic pathways involving 
the metabolism of bile acids, sugars, amino acids, fatty acids with the most significant impact 
on the steroidal metabolic pathway. Additionally, a marginally increased level of CYP 
metabolising enzymes was observed after antibiotic treatment. Metatranscriptomic 
approaches have also been employed to analyse gut microbiome samples exposed to various 
drugs and have identified multiple candidate genes for their microbial metabolism (Maurice 
et al. 2013). This ex vivo study investigated the impact of short-term exposure of human 
faeces to various non-antibiotic drugs (10 mg/ml concentration used for all the following 
drugs) including cardiac glycosides (digoxin and digitoxin), an anthelmintic (levamisole), 
gastric-acid suppressant (nizatidine), an analgesic (phenacetin), and sulfasalazine. Even 
though these drugs did not directly alter microbial physiology (i.e. membrane integrity and 
polarity), even at very high concentrations, they all significantly changed the expression of 
microbial genes linked to drug import and metabolism. For example, sulfasalazine was 
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demonstrated to induce expression of thioredoxins and nitrate reductases while nizatidine, 
subject to bacterially-mediated N-oxide bond cleavage, upregulated the expression of drug 
enzymes and transporters acting on nitrogen bonds (Maurice et al. 2013). This finding 
supports the earlier hypothesis that drugs may shift the microbiota to favour the abundance of 
taxa involved in its metabolism. Furthermore, this altered metabolic capacity of the 
microbiota could consequently affect not only the pharmacokinetics of subsequent doses of 
the drug itself (a phenomenon referred to as autoinduction) but also the pharmacokinetics of 
co-administered medication that are substrates of the same metabolic pathway or transporter. 
 
4 Implications of the Drug-Gut Microbiome Relationship for 
Neuropharmacology 
 
4.1 Effect of antibiotics on inflammation and brain-gut axis: 
Recent studies have explored the impact of the antibiotics on the inflammasome-gut 
microbiota regulation of brain function and behaviour. Wong et al. investigated whether the 
caspase-1 antagonist and tetracycline antibiotic, minocycline, has a protective effect on the 
stress response by modulating the microbiota-gut-brain axis (Wong et al. 2016). 
Minocycline-treatment (5 mg/kg via i.p. injection for 21 days) increased the abundance of 
Akkermansia spp., which is consistent with attenuation of inflammation, and ameliorated the 
stress-induced depressive-like behaviour in wild-type mice. This suggests that the 
behavioural effects of minocycline may be mediated via the microbiota and not just via its 
effects on the central nervous system microglial activation (Inta et al. 2017). 
 
4.2 Psychoactive drugs and the gut-brain axis: Impact on intestinal barrier 
function 
Several psychoactive drugs have marked effects on the intestinal barrier (for example 
permeability and mucus secretion) and alter GI transit. Serotonergic psychoactive drugs have 
been utilised as a treatment in functional GI diseases; the selective serotonin reuptake 
inhibitor (SSRI), paroxetine, increases the motility rate of the small intestine whilst tricyclic 
antidepressants are known to delay gastric emptying (Grover and Camilleri 2013). 
Concurrently, the gut microbiota modulates intestinal permeability with consequential effects 
on the absorption and metabolism of psychoactive drugs. Maintenance of intestinal mucosal 
integrity is important for appropriate absorption of psychoactive drugs in the small intestine. 
The gut microbiota challenges the intestinal barrier function via induced alterations in 
intestinal pH and effects on intestinal epithelial integrity (Cani et al. 2008; Carvalho et al. 
2012). The presence of the bacterium H. pylori decreases the absorption of the anti-
Parkinson’s drug and dopamine precursor, levodopa. It was hypothesised H. pylori might 
alter gastric motility, disrupt the duodenal mucosa or produce reactive oxygen species which 
may inactivate levodopa (Hamlet et al. 1999; Miyaji et al. 1999). More recently, eradication 
of H. pylori has been shown to significantly improve clinical symptoms of patients with 
Parkinson’s disease and improve levodopa efficacy (Hashim et al. 2014). Additionally, 
several neuropsychiatric disorders have been associated with a dysfunctional intestinal 
barrier; acute stress is associated with expression of the tight junction proteins, zonula 
occludens-1 and occludin, in the duodenal mucosa of rats subjected to water immersion 
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restraint stress (Lee et al. 2013). Moreover, corticotrophin-releasing hormone receptors 
mediate the colonic barrier dysfunction observed in response to maternal separation-induced 
mild stress (Söderholm et al. 2002). Hence, both the gut microbiota and psychiatric disorders 
modulate intestinal permeability and barrier function which in turn may precipitate changes 
in the absorption of psychoactive drugs (Kelly et al. 2015). 
 
4.3 Impact of CNS-related disorders on the composition of the gut microbiota:  
In addition to drug-induced changes in the gut microbiome, alterations in the composition of 
the gut microbiota have also been associated with neurological dysfunction and psychiatric 
disorders (Cenit et al. 2017). Kelly et al. observed decreased richness and diversity of the gut 
microbiota in depressed patients and numerous studies have identified an altered microbiota 
composition in children with autism spectrum disorder (ASD); increased abundance of 
Lactobacillus and Desulfovibrio spp. has correlated with autism severity (Finegold 2011; 
Tomova et al. 2015; Kelly et al. 2016). The gut microbiota has also been identified as a 
potential regulator of other neuropsychiatric disorders, for example, schizophrenia (Dinan et 
al. 2014; Shen et al. 2018). It is yet to be established whether these disease-associated 
changes to the gut microbiota are involved in the initiation of disease pathogenesis (altered 
microbiota state precipitating changes in brain development or function) or occur because of 
the disease (i.e. whether changes in gut microbiota arise following alterations in brain 
development or function). Alternatively, the microbiota changes could also occur as a result 
of dietary patterns or medication (Mayer et al. 2015). As both the CNS-related disease itself 
and the pharmacological treatment of the disease can alter the composition of the microbiota, 
it is thus essential to account for independent effects of the disease or drug treatment in both 
animal and human studies. 
 
4.4 Microbial metabolism of psychoactive drugs: 
Few studies have offered mechanistic insight into the microbiota-mediated metabolism of 
psychoactive drugs however those that have are summarised in Table 2. In most cases, the 
specific microbial species, or microbial-derived enzymes, responsible for the metabolism of 
psychoactive drugs by the gut microbiome are unknown. 
There is evidence to suggest benzodiazepines are subject to microbiota-mediated drug 
metabolism. Older studies have demonstrated the microbiota-mediated nitro-reduction of the 
hypnotics, clonazepam and nitrazepam, to their corresponding 7-amino metabolite 
derivatives. Elmer et al. administered radiolabelled clonazepam and quantified the production 
of the nitro-reduced clonazepam metabolites in GF rats before and after colonisation with 
faecal microbiota. The production of these metabolites increased significantly from 15% in 
GF mice to 77% after microbial colonisation (Elmer and Remmel 1984). Similarly, the 
reduction of the hypnotic, nitrazepam, to 7-aminonitrazepam and 7-acetylaminonitrazepam 
was shown to be mediated by several anaerobic bacteria isolated from human gut isolates 
including species from the Clostridium, Bacteroides and Eubacterium genera. The authors 
identified the bacterium, Clostridium leptum, as having highly specific nitroreductase activity 
(Rafii et al. 1997). A previous study highlighted antibiotics can deplete the activity of this 
microbial enzyme (Takeno and Sakai 1991). The production of nitro-reduced nitrazepam 
metabolites in pregnant rats, following an oral dose of nitrazepam 300 mg/kg, was quantified 
before and after antibiotic treatment, which was given to diminish nitro-reductase enzymatic 
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activity. The levels of 7aminonitrazepam and 7acetylaminonitrazepam decreased from 30% 
pre-treatment to 2% after antibiotic treatment. 
 
4.5 Impact of psychoactive drugs on the composition of the gut microbiota: 
Antidepressants and antipsychotics are associated with distinct gut microbiota signatures. 
Gastric acid suppressants, antipsychotics, and antidepressants have repeatedly been 
confirmed as the three non-antibiotic drug classes most associated with the abundance of 
single taxa. Antipsychotics, for example, were associated with the abundance of Prevotella, 
an unclassified member of the Desulfovibrionaceae family and Victivallis genus in an 
observation-based study in an elderly (≥ 65 years) hospitalised cohort (Ticinesi et al. 2017).  
On the other hand, antidepressant-use in this cohort significantly correlated with the 
increased abundance of five specific bacterial taxa belonging to the Helicobacter, 
Asteroleplasma, Marinilactibacillus genera and unclassified members of both the Bacillus 
class and Succinivibrionaceae family. In an observation based study in community-dwelling 
patients (mean age 52 years), the SSRI antidepressant, citalopram, was associated with a 
significantly increased relative abundance of the Enterobacteriaceae family in comparison to 
patients not taking any medication (Rogers and Aronoff 2016). The specific use of the 
antipsychotics, olanzapine, and risperidone, causes a shift in the gut microbiota composition 
to a state previously shown to be associated with obesity in both rat and human (12.2 (SD 
2.5) years) in vivo studies (Davey et al. 2012; Bahr et al. 2015a). Chronic olanzapine 
treatment of rats (2-4 mg/kg/day) and mice (50 mg/kg HFD) was associated with an increase 
in Firmicutes, a decrease in Bacteroidetes and an overall reduction in biodiversity (Davey et 
al. 2012; Morgan et al. 2014). Similarly, chronic risperidone treatment (approximately 80 µg 
risperidone/day for 58 days) resulted in a 22.4% decrease in Bacteroidetes and a reciprocal 
32.6% increase in Firmicutes in the risperidone-treated mice relative to control mice (Bahr et 
al. 2015b).  
The mechanisms underpinning these changes in bacterial abundance or diversity induced by 
psychoactive drugs are not fully understood, but both these drug classes have shown in vitro 
antimicrobial activity. There is preliminary evidence to suggest that olanzapine has 
antimicrobial activity. Morgan et al. found olanzapine inhibited the in vitro growth of two 
commensal strains, E. coli and Enterococcus faecalis. The dose investigated, however, was 
above the recommended dosage range of 5-20 mg/day and therefore whether clinically-
relevant doses of olanzapine would still possess antimicrobial activity remains to be tested 
(Morgan et al. 2014). Similarly, the phenothiazine group of antipsychotics exerted 
antimicrobial effects at higher than clinically-relevant drug doses (Amaral et al. 2004). The 
phenothiazine antipsychotic, chlorpromazine was the first psychoactive drug associated with 
antibacterial properties. S. aureus, Mycobacterium, and some gram-negative rods such as 
Shigella spp. have been identified as the bacteria most susceptible to the antibacterial activity 
of phenothiazine antipsychotics (Amaral et al. 2004). Evidence suggests phenothiazine 
antipsychotics may mediate their effects on microbial growth through the alteration of 
bacterial morphology (phenothiazines cause filamentation of E. coli) or inhibition of bacterial 
adherence to epithelial cells (phenothiazines reduce E. coli adherence to urinary epithelium) 
(Amaral et al. 2004). 
Similarly, antidepressant-induced changes in gut microbiota may be mediated by direct 
antimicrobial activity. SSRIs (including paroxetine, sertraline, and fluoxetine) are associated 
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with a broad-spectrum of antibacterial activity, including activity against strains of 
Staphylococcus, Enterococcus, Clostridium, Pseudomonas and Citrobacter (Munoz-Bellido 
et al. 2000). Sertraline can also influence microbial growth by acting synergistically with 
other antibiotics. Sertraline increased the efficacy of co-administered tetracycline and 
fluoroquinolone antibiotics against, a pathogenic strain associated with urinary tract 
infections, Corynebacterium urealyticum (Munoz-Bellido et al. 1996). The inhibition of 
efflux pumps in bacterial cells by sertraline is hypothesised as one causative mechanism. 
SSRIs may also interfere with the biosynthesis of the slime layer on bacteria (Munoz-Bellido 
et al. 2000); the disruption of the slime layer may also act to increase bacterial susceptibility 
to co-administered antibiotics. Apart from SSRIs, other antidepressants have antimicrobial 
effects, including monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants 
(TCAs). The inhibition of cell wall synthesis and anti-plasmid activity have been proposed as 
mechanisms underlying the antimicrobial activity of the MAOI, iproniazid, and the TCA drug 
class respectively (Molnar 1988; Macedo et al. 2017). 
Psychotropic drugs can also modulate the activity and pathogenicity of microbes which can 
precipitate changes in the gut microbiome. Sertraline can alter the in-vitro pathogenicity of 
fungi, for example, by significantly affecting the virulence properties associated with 
Candida including decreased hyphal elongation and reduced secretion of aspartyl proteinases, 
thereby preventing fungal adherence and tissue invasion of Candida spp. (Lass-Florl et al. 
2003). 
4.6 The Impact of psychoactive drug-microbiota interactions: Implications for drug 
response and toxicity 
The growing evidence of the complex relationship between drugs and the gut microbiome, 
illustrated in Figure 1, underscores the importance of considering the gut microbiota as an 
additional factor contributing to the inter-individual variation observed in drug metabolism 
and response.  
The interaction of psychoactive drugs with the gut microbiota has implications for drug 
absorption and bioavailability. As mentioned previously, levodopa is one of the most studied 
psychoactive drugs that interact with the gut microbiome. Research illustrating the 
metabolism of this drug by the gut microbiota-mediated dehydroxylation dates back to the 
1970s (Goldin et al. 1973). Follow-on studies found decreased plasma levels of the drug with 
the presence of H. pylori, attributed to levodopa-mediated interaction with the bacterial 
surface adhesions (Niehues and Hensel 2009). 
Antidepressants are associated with considerable inter-individual variation in drug response 
and a lack of efficacy; it’s estimated that antidepressants are only 20-30% more effective than 
placebo (Arroll et al. 2005). Pharmacogenetics, although still in its relative infancy, has thus 
far proven unsuccessful in identifying and optimising factors that may hinder antidepressant 
efficacy. The pathophysiology of major depression disorder (MDD) has, however, been 
linked to alterations in the gut microbiota composition; MDD is associated with increased 
levels of Bacteroidetes and Enterobacteriaceae and decreased levels of Firmicutes. This 
altered microbiota state has been linked to increased gut permeability, a factor that can dictate 
intestinal drug transport and absorption (Jiang et al. 2015). Continued metabolomic and 
metagenomic analysis of the microbiome and further pharmacomicrobiomic based-studies 
may thus offer some additional insight. 
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The gut microbiota has also been implicated in the propagation of the side effects and toxicity 
of psychoactive drugs. With patient adherence to psychotropic therapy estimated to be only 
30%, poor compliance has been linked to the unfavourable side-effect profile associated with 
these drugs (Weich et al. 2007). As previously highlighted, antibiotic treatment of rats 
attenuated both the microbial metabolism and the teratogenicity-associated adverse effect of 
nitrazepam and its metabolites (Elmer and Remmel 1984). More recently, antipsychotic-
induced metabolic dysfunction has been linked to shifts in the composition of the gut 
microbiota. The role of the gut microbiome in the development of olanzapine-induced weight 
gain was elucidated when olanzapine-treated GF mice did not gain weight but did so upon 
colonisation with caecal microbiota (Morgan et al. 2014). Furthermore, an antibiotic cocktail 
co-administrated with olanzapine, to chemically deplete the gut microbiota, attenuated the 
metabolic side effects associated with the drug treatment alone in rats; increased weight gain, 
increased uterine fat deposition and increased plasma free fatty acid levels were side-effects 
attenuated in microbiota-depleted rats (Davey et al. 2013).  
A recent follow-on study by Kao et al. investigated whether treatment with a prebiotic, 
BimunoTM galacto-oligosaccharides (B-GOS), modified the olanzapine-induced weight gain 
(Kao et al. 2018). Female rats were treated with B-GOS (0.5 g/kg/day) for 21 days, in 
conjunction with administration of olanzapine (10 mg/kg once daily via i.p. injection) or 
saline on days 8-21. B-GOS treatment significantly attenuated the drug-induced weight gain 
without altering the antagonism of central serotoninergic receptors necessary for drug 
efficacy. B-GOS treatment alone altered the microbiota composition; differences in the 
abundance of Bifidobacterium spp. and Firmicutes spp. were evident in B-GOS only treated 
rats in comparison to both water-only and B-GOS-olanzapine-treated rats. Contrary to the 
previous findings by Davey et al. and Morgan et al. discussed above, administration of 
olanzapine, however, did not significantly alter the composition of the faecal microbiota, 
albeit different dosage regimens were employed in the respective studies (Davey et al. 2013; 
Morgan et al. 2014). Furthermore, the authors deduced, contrary to their hypothesis, that 
elevated levels of the SCFA, acetate, may mediate the olanzapine-induced weight gain. 
Considering the risks associated with antibiotic resistance, prebiotic treatment may constitute 
a more suitable adjunctive therapy in comparison to long-term antibiotic use to improve 
patient tolerance to olanzapine. 
Both olanzapine-induced and risperidone-induced weight gain correlated with an altered gut 
microbiota composition (Davey et al. 2012; Bahr et al. 2015b). Suppressed energy 
expenditure, induced by the gut microbiota, was found to cause the observed weight gain in 
risperidone-treated mice. Furthermore, faecal microbiota transplantation (FMT) from 
risperidone-treated mice to treatment-naive mice induced weight gain and suppressed energy 
expenditure in the FMT-recipient mice (Bahr et al. 2015b). On the premise that some 
antidepressants (e.g. SSRIs and TCAs) are associated with similar effects to these 
antipsychotics, i.e. changes in the gut microbiota and drug-induced weight gain, it may be 
timely to extend these studies to antidepressants. 
Conclusion/Future Directions 
Research has identified many clinically relevant drugs, including psychotropics, which are 
metabolised by the microbiome, often via as yet unknown mechanisms. There remains a need 
to establish the microorganism responsible for metabolism and identify the molecular 
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mechanisms involved. While medication-use can precipitate changes in the abundance and 
diversity of a wide array of different bacterial phyla, the resultant impact of these 
compositional changes on drug response and patient outcomes requires further study. 
Matching specific microbial genes or enzymes, which may dictate drug response, to specific 
bacterial phyla could lead to greater understanding of the consequential impact of 
disturbances in the microbiome on patient outcomes and provide additional impetus to 
explore the contribution of these important, but underappreciated, drug-microbiome 
interactions to the inter-individual variability observed in drug response.  
Nomenclature of Targets and Ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017). 
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Drug (or Metabolite) Substrate: Ref: 
β-glucuronidase Remove glucuronic acid moiety 
from hepatic phase 2 metabolites 
irinotecan (SN-38 glucuronide) 
NSAIDS e.g. indomethacin 
 and diclofenac 
(Yamamoto et al. 
2008; Saitta et al. 
2014) 
Azoreductase Reduction of azo or quinone 
bonds 
Azo-containing drugs e.g. Olsalazine 
(5ASA prodrug)  
Nitrofuran antibiotics e.g., 
nitrofurazone and nitrofurantoin 
Ester containing prodrugs 
(Ryan 2017) 
Carboxylesterase Hydrolyse ester, thioester, amide, 
or carbamate containing drugs to 
respective free acids  
Hydrolyse esters to carboxylic 
acids 
Aspirin,  
Ester containing prodrugs 
(Imai and Ohura 
2010; Laizure et 
al. 2013; Kim et 
al. 2016) 
Nitroreductase Reduction of nitro group Metronidazole 
Benzodiazepines 
(Koch et al. 
1979; Elmer and 
Remmel 1984; 
Takeno et al. 
1990) 
N-acetyltransferase Transfer of acetyl group to 
nitrogen or oxygen atom of 
primary arylamines, hydrazines 
and N-hydroxylated metabolites 
5-aminosalicylic acid 
 
(van Hogezand et 
al. 1992; 
Deloménie et al. 
2001) 
 




Bio-activation of sulfur- and 
selenocysteine derivatives 
(Mikov 1994) 
Sulfatases Hydrolysis of sulfate esters 
utilising formylglycine 
Sulfate ester hepatic metabolites (Ulmer et al. 
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Table 2: Psychoactive drugs are subject to direct metabolism by the gut microbiota. 











Risperidone Anti-Psychotic In vivo; rats & 
dogs 
unknown Isoxazole scission of 
benzisoxazole ring 
system 




Hypnotic  In vivo; rats unknown Nitro-reductase 
mediated reduction 
(Takeno et al. 1990) 









In vivo; rats unknown Decarboxylation and 
p-dehydroxylation 
mediated conversion 
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Fig. 1:  The complex interplay between drugs and the gut microbiota. The reciprocal 
relationship between drugs and the gut microbiome is comprised of both microbiota-mediated 
alterations to drug pharmacokinetics and drug-mediated alterations to the 
function/composition of the gut microbiome. These interactions can occur by both direct 
(illustrated by solid white arrows with black outline) and indirect/secondary (illustrated by 
curved line arrows) mechanisms. “Microbiota-Drug Interactions”: the microbiota can directly 
metabolise drugs through bacterial-derived enzymes (e.g. nitro-reductase mediated 
metabolism of clonazepam) but can also indirectly affect drug metabolism through the 
alteration of the hosts capacity to metabolise drugs (curved-up line arrow) i.e. (PK effect); 
microbial-derived metabolites (e.g. SCFAs and secondary bile acids) may be potential 
mediators of this effect. The interactions between the host and gut microbiome are 
responsible for the enterohepatic recirculation of drugs e.g. the hepatic-glucuronidated 
irinotecan metabolite is deconjugated by β-glucuronidase enzymes expressed by the gut 
microbiota. “Drug-Microbiota Interactions”: The mechanisms underpinning the drug-
mediated changes to the function and composition the gut microbiome are yet to be fully 
elucidated. Drugs can have antibacterial properties that directly affect the composition of the 
gut microbiota (e.g. sertraline). Drugs can also alter the physiological properties or functions 
of host organs (i.e. PD effect) (e.g. PPI-mediated alterations to gastric acid production and 
pH, NSAID-induced changes to mucosal integrity) which may, in turn, precipitate secondary 
effects to the composition of the gut microbiota (illustrated by the curved-down line arrow).  
PK- Pharmacokinetic; PD-Pharmacodynamic 
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Ligand/Drug links for BJP Review Article: 



















aryl hydrocarbon receptor 
bilirubin 
Constitutive androstane receptor 























Drugs appearing in tables (not referenced in main text: 
Irinotecan 
Indomethacin 
diclofenac 
methamphetamine 
 
